MYC in DLBCL: Partners matter

Blood

Volumn 126, Issue 22, 2015, Pages 2439-2440

  Campo, Elias ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6; IMMUNOGLOBULIN;

B LYMPHOCYTE ACTIVATION; CANCER CHEMOTHERAPY; GENE REARRANGEMENT; GENE TRANSLOCATION; GERMINAL CENTER; HUMAN; IMMUNOGLOBULIN GENE; LARGE CELL LYMPHOMA; MORPHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; FEMALE; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOGLOBULINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PROTO-ONCOGENE PROTEINS C-MYC; TRANSLOCATION, GENETIC;

EID: 84949024000     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-671362     Document Type: Review

References (10)

1. Copie-Bergman C, Cuillière-Dartigues P, Baia M, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015;126(22):2466-2474.
2. Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013;122(24):3884-3891.
3. Dunleavy K. Double-hit lymphomas: current paradigms and novel treatment approaches. Hematology Am Soc Hematol Educ Program. 2014;2014:107-112.
4. Swerdlow SH. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology Am Soc Hematol Educ Program. 2014;2014:90-99.
5. Tzankov A, Xu-Monette ZY, Gerhard M, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014;27(7):958-971.
6. Pedersen MØ, Gang AO, Poulsen TS, et al. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC-or double-hit MYC/BCL2 translocations. Eur J Haematol. 2014;92(1):42-48.
7. Aukema SM, Kreuz M, Kohler CW, et al; Molecular Mechanisms in Malignant Lymphomas Network Project. Biological characterization of adult MYC-translocationpositive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99(4):726-735.
8. Pillai RK, Sathanoori M, Van Oss SB, Swerdlow SH. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol. 2013;37(3):323-332.
9. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273-2279.
10. Momose S, Weißbach S, Pischimarov J, et al. The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum. Leukemia. 2015;29(8):1789-1791.